MIRM - Mirum Pharmaceuticals

-

$undefined

N/A

(N/A)

Mirum Pharmaceuticals NasdaqGM:MIRM Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Location: 950 Tower Lane, Foster City, CA, 94404, United States | Website: https://www.mirumpharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.269B

Cash

277.7M

Avg Qtr Burn

-1.712M

Short % of Float

15.85%

Insider Ownership

1.98%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
LIVMARLI (Maralixibat) Details
Liver disease, Progressive familial intrahepatic cholestasis

Approved

Quarterly sales

CTEXLI™ (chenodiol) Tablets Details
Cerebrotendinous xanthomatosis

Approved

Quarterly sales

LIVMARLI (Maralixibat) Details
ALGS (Alagille syndrome), PFIC (Progressive Familial Intrahepatic Cholestasis)

Approved

Quarterly sales

Volixibat Details
Primary biliary cholangitis, Liver disease

Phase 2b

Data readout

Volixibat Details
Liver disease, Primary sclerosing cholangitis

Phase 2b

Update

MRM-3379 Details
Fragile X syndrome

Phase 2

Initiation

Volixibat Details
Liver disease, Intrahepatic Cholestasis of Pregnancy

Failed

Discontinued

LIVMARLI (Maralixibat) Details
Rare diseases, Bile duct disease

Failed

Discontinued